<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        233-11-94
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1994
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        SANDOSTATIN 0.1MG-ML AMP
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        OCTREOTIDE ACETATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        0.1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection/infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Ampoule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        153.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="NOVARTIS" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            NOVARTIS
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 439]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Novartis Saudi Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            NOVARTIS
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        H01CB02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Sandostatin is a synthetic compound derived from somatostatin, a substance normally found in the human body which inhibits the effects of certain hormones such as growth hormone. The advantages of Sandostatin over somatostatin are that it is stronger and its effects last longer.</p><p>&nbsp;</p><p><strong>Sandostatin is used</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in <strong>acromegaly</strong>, a condition where the body produces too much growth hormone. Normally, growth hormone controls growth of tissues, organs, and bones. Too much growth hormone leads to an increase in the size of bones and tissues, especially in the hands and feet. Sandostatin markedly reduces the symptoms of acromegaly, which include headache, excessive perspiration, numbness of the hands and feet, tiredness, and joint pain.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to relieve symptoms associated with some <strong>tumours of the gastrointestinal tract</strong> (e.g. carcinoid tumours, VIPomas, glucagonomas, gastrinomas, insulinomas). In these conditions, there is overproduction of some specific hormones and other related substances by the stomach, bowels, or pancreas. This overproduction upsets the natural hormonal balance of the body and results in a variety of symptoms, such as flushing, diarrhoea, low blood pressure, rash, and weight loss. Treatment with Sandostatin helps to control these symptoms.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to prevent <strong>complications following surgery of the pancreas gland</strong>. Treatment with Sandostatin helps to lower the risk of complications (e.g. abscess in the abdomen, inflammation of the pancreas gland) after the surgery.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to stop bleeding and to protect from <strong>re‑bleeding from ruptured gastro‑oesophageal varices</strong> in patients suffering from cirrhosis (chronic liver disease). Treatment with Sandostatin helps to control bleeding and reduce transfusion requirements.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to treat pituitary tumours that produce too much thyroid‑stimulating hormone (TSH). Too much thyroid‑stimulating hormone (TSH) leads to hyperthyroidism.</p><p>Sandostatin is used to treat people with pituitary tumours that produce too much thyroid‑stimulating hormone (TSH):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; when other types of treatment (surgery or radiotherapy) are not suitable or have not worked;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; after radiotherapy, to cover the interim period until the radiotherapy becomes fully effective.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Do not use Sandostatin:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to octreotide or any of the other ingredients of this medicine (listed in section 6).</p><p>&nbsp;</p><p><strong>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Take special care with Sandostatin</strong></p><p>&nbsp;</p><p>Talk to your doctor before using Sandostatin:</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you know that you have gallstones now, or have had them in the past or experience any complications like fever, chills, abdominal pain, or yellowing of your skin or eyes; tell your doctor, as prolonged use of Sandostatin may result in gallstone formation. Your doctor may wish to check your gallbladder periodically.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have problems with your blood sugar levels, either too high (diabetes) or too low (hypoglycaemia). When Sandostatin is used to treat bleeding from gastro‑oesophageal varices; monitoring of blood sugar level is mandatory.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a history of vitamin B12 deprivation your doctor may wish to check your vitamin B12 level periodically.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Octreotide may lower your heart rate and at very high doses may cause abnormal heart rhythm. Your doctor may monitor your heart rate during treatment.</p><p><strong>Test and checks</strong></p><p>&nbsp;</p><p>If you receive treatment with Sandostatin over a long period of time, your doctor may wish to check your thyroid function periodically.</p><p>&nbsp;</p><p>Your doctor will check your liver function.</p><p>Your doctor may wish to check your pancreatic enzyme function.</p><p><strong>Children</strong></p><p>There is little experience with the use of Sandostatin in children.</p><p>&nbsp;</p><p><strong>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Using other medicines</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p>You can generally continue taking other medicines while on Sandostatin. However, certain medicines, such as cimetidine, ciclosporin, bromocriptine, quinidine and terfenadine have been reported to be affected by Sandostatin.</p><p>&nbsp;</p><p>If you are taking a medicine to control your blood pressure (e.g. a beta blocker or a calcium channel blocker) or an agent to control your fluid and electrolyte balance, your doctor may need to adjust the dosage.</p><p>&nbsp;</p><p>If you are diabetic, your doctor may need to adjust your insulin dosage.</p><p>If you are going to receive lutetium (<sup>177</sup>Lu) oxodotreotide, a radiopharmaceutical therapy, your doctor may stop and/or adapt Sandostatin treatment.</p><p><strong>d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Pregnancy and breast‑feeding</strong></p><p>If you are pregnant or breast‑feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.</p><p>&nbsp;</p><p>Sandostatin should only be used during pregnancy if clearly needed.</p><p>&nbsp;</p><p>Women of child‑bearing age should use an effective contraceptive method during treatment.</p><p>&nbsp;</p><p>Do not breast-feed while using Sandostatin. It is not known whether Sandostatin passes into breast milk.</p><p>&nbsp;</p><p><strong>e.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Driving and using machines</strong></p><p>Sandostatin has no or negligible effects on the ability to drive and use machines. However, some of the side effects you may experience while using Sandostatin, such as headache and tiredness, may reduce your ability to drive and use machines safely.</p><p>&nbsp;</p><p><strong>f.&nbsp;&nbsp; </strong><strong>Important information about some of the ingredients of Sandostatin</strong></p><p><strong>Sandostatin contains sodium</strong></p><p>This medicine contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per ampoule/vial, that is to say essentially &ldquo;sodium-free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always &nbsp;use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p>Depending on the condition being treated, Sandostatin is given by:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; subcutaneous (under the skin) injection or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; intravenous (into a vein) infusion.</p><p>&nbsp;</p><p>If you have liver cirrhosis (chronic liver disease), your doctor may need to adjust your maintenance dose.</p><p>&nbsp;</p><p>Your doctor or nurse will explain to you how to inject Sandostatin under the skin, but infusion into a vein must always be performed by a health care professional.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Subcutaneous injection</strong></p><p>&nbsp;</p><p>The upper arms, thighs, and abdomen are good areas for subcutaneous injection.</p><p>&nbsp;</p><p>Choose a new site for each subcutaneous injection so that you do not irritate a particular area. Patients who will be injecting themselves must receive precise instructions from the doctor or nurse.</p><p>&nbsp;</p><p>If you store the medicine in the refrigerator, it is recommended that you allow it to reach room temperature before using it. This will reduce the risk of pain at the site of injection. You can warm it up in your hand but do not heat it.</p><p>&nbsp;</p><p>A few people experience pain at the site of the subcutaneous injection. This pain usually only lasts a short time. If this happens to you, you can relieve this by gently rubbing the site of injection for a few seconds afterwards.</p><p>&nbsp;</p><p>Before using a Sandostatin ampoule, check the solution for particles or a change of colour. Do not use it if you see anything unusual.</p><p>&nbsp;</p><p><strong>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>If you use more Sandostatin than you should</strong></p><p>The symptoms of overdose are: irregular heart beat, low blood pressure, cardiac arrest, reduced supply of oxygen to the brain, severe upper stomach pain, yellow skin and eyes, nausea, loss of appetite, diarrhoea, weakness, tiredness, lack of energy, weight loss, abdominal swelling, discomfort and high level of lactic acid in the blood&nbsp;and abnormal heart rhythm.</p><p>&nbsp;</p><p>&nbsp;</p><p>If you think that an overdose has happened and you experience such symptoms, tell your doctor straight away.</p><p>&nbsp;</p><p><strong>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>If you forget to use Sandostatin</strong></p><p>Administer one dose as soon as you remember, and then continue as usual. It will not do any harm if you miss a dose, but you could get some temporary re‑appearance of symptoms until you get back on schedule.</p><p>&nbsp;</p><p>Do not inject a double dose of Sandostatin to make up for forgotten individual doses.</p><p>&nbsp;</p><p><strong>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>If you stop using Sandostatin</strong></p><p>If you interrupt your treatment with Sandostatin your symptoms may come back. Therefore, do not stop using Sandostatin unless your doctor tells you to.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, nurse or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Some side effects could be serious. Tell your doctor straight away if you get any of the following:</strong></p><p>&nbsp;</p><p><strong>Very common </strong>(may affect more than 1 in 10&nbsp;people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gallstones, leading to sudden back pain.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Too much sugar in the blood.</p><p>&nbsp;</p><p><strong>Common </strong>(may affect up to 1 in 10&nbsp;people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Underactive thyroid gland (hypothyroidism) causing changes in heart rate, appetite or weight; tiredness, feeling cold, or swelling at the front of the neck.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in thyroid function tests.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the gallbladder (cholecystitis); symptoms may include pain in the upper right abdomen, fever, nausea, yellowing of the skin and eyes (jaundice).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Too little sugar in the blood.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Impaired glucose tolerance.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Slow heart beat.</p><p>&nbsp;</p><p><strong>Uncommon </strong>(may affect up to 1 in 100&nbsp;people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thirst, low urine output, dark urine, dry flushed skin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fast heart beat.</p><p>&nbsp;</p><p><strong>Other serious side effects</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypersensitivity (allergic) reactions including skin rash.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A type of an allergic reaction (anaphylaxis) which can cause difficulty in swallowing or breathing, swelling and tingling, possibly with a drop in blood pressure with dizzinessor loss of consciousness.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An inflammation of the pancreas gland (pancreatitis); symptoms may include sudden pain in the upper abdomen, nausea, vomiting, diarrhoea.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Liver inflammation (hepatitis); symptoms may include yellowing of the skin and eyes (jaundice), nausea, vomiting, loss of appetite, generally feeling unwell, itching, light‑coloured urine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Irregular heart beat.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low level of platelet count in blood; this could result in increased bleeding or bruising.</p><p>&nbsp;</p><p>Tell your doctor straight away if you notice any of the side effects above.</p><p><strong>&nbsp;</strong></p><p><strong>Other side effects:</strong></p><p>Tell your doctor, pharmacist or nurse if you notice any of the side effects listed below. They are usually mild and tend to disappear as treatment progresses.</p><p>&nbsp;</p><p><strong>Very common </strong>(may affect more than 1 in 10&nbsp;people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abdominal pain.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Constipation.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Flatulence (wind).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Local pain at the injection site.</p><p>&nbsp;</p><p><strong>Common </strong>(may affect up to 1 in 10&nbsp;people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stomach discomfort after meal (dyspepsia).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling of fullness in the stomach.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fatty stools.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loose stools.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Discolouration of faeces.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss of appetite.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Change in liver function tests.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hair loss.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shortness of breath.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weakness.</p><p>&nbsp;</p><p>If you get any side effects, please tell your doctor, nurse or pharmacist.</p><p>&nbsp;</p><p>A few people experience pain at the site of the subcutaneous injection. This pain usually only lasts a short time. If this happens to you, you can relieve this by gently rubbing the site of injection for a few seconds afterwards.</p><p>&nbsp;</p><p>If you are administering Sandostatin by subcutaneous injection, it may help to reduce the risk of gastrointestinal side effects if you avoid eating meals around the time of injection. It is therefore recommended that you inject Sandostatin between meals or when you go to bed.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Store in the original package in order to protect from light.</p><p>Store in a refrigerator (2&deg;C to 8&deg;C). Do not freeze.</p><p>The ampoule (100 micrograms/1ml) may be stored below 30&deg;C for up to two weeks.</p><p>The ampoules should be used immediately after opening.</p><p>&nbsp;</p><p>Diluted solutions should be used immediately after preparation.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the label and carton after EXP.&nbsp; The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Do not use this medicine if you notice particles or a change of colour.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is octreotide.</p><p>Sandostatin 0.1mg/ml:&nbsp; 1&nbsp;ml solution contains 100 microgram octreotide.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are</p><p>in ampoules: lactic acid, mannitol (E421), sodium hydrogen carbonate, water for injections</p><p>in multidose vials: lactic acid, phenol, mannitol (E421), sodium hydrogen carbonate, water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Ampoules:
Colourless glass containing clear, colourless solution
Packs of three, five, six, ten, twenty and fifty ampoules.
Multipacks of ten packs, each containing three ampoules. 

Multidose vials:
Colourless glass with latex free rubber closure (isobutylene-isoprene rubber) containing clear, colourless solution.
Packs of one and five vials.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The Marketing Authorization Holder for this Product is Novartis Pharma.</p><p>www.Novartis.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved by MHRA in 07/2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">دواء ساندوستاتين هو مُرَكَّب تخليقي مُشتَق من مادة السوماتوستاتين، وهي مادة توجد عادةً في الجسم البشري وتثبط تأثيرات بعض الهرمونات مثل هرمون النمو. المميزات التي يتفوق بها دواء ساندوستاتين على سوماتوستاتين هي أن فعَّاليته أقوى وتأثيراته تستمر لفترة أطول.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يُستَخدَم </strong><strong>دواء</strong><strong> ساندوستاتين</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة <strong>ضخامة الأطراف</strong>، وهي حالة ينتج فيها الجسم كمية أكبر مما يجب من هرمون النمو. عادةً يتحكم هرمون النمو في نمو الأنسجة والأعضاء والعظام. يُؤدي وجود كمية أكبر مما يجب من هرمون النمو إلى زيادة في حجم العظام والأنسجة، لا سيَّما في اليدين والقدمين. يقلل دواء ساندوستاتين بشكل ملحوظ أعراض ضخامة الأطراف، والتي تتضمن الصُّداع والتعرق الزَّائد والتَّنميل في اليدين والقدمين والتَّعب وألم المفاصل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لتخفيف الأعراض المُصاحِبة لبعض <strong>أورام الجهاز الهضمي</strong> (على سبيل المثال: الأورام السرطاوية، أورام الخلايا المنتجة للببتيد المعوي الفعَّال في الأوعية، أورام الخلايا المفرزة للجلوكاجون، أورام الخلايا المفرزة للجاسترين، أورام الخلايا المفرزة للأنسولين). في هذه الحالات، يكون هناك فرط إنتاج لبعض الهرمونات المُحَددة وغيرها من المواد ذات الصلة عن طريق المعدة أو الأمعاء أو البنكرياس. يُؤدي فرط الإنتاج إلى إخلال التَّوازن الهرموني الطبيعي بالجسم وينتج عنه مجموعة متنوعة من الأعراض، مثل: احمرار الجلد والإسهال وانخفاض ضغط الدَّم والطفح الجلدي وفقدان الوزن. يُساعِد العلاج بدواء ساندوستاتين على التَّحكم في هذه الأعراض.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; للوقاية من <strong>المضاعفات التَّالية لجراحة البنكرياس</strong>. يُساعِد العلاج بدواء ساندوستاتين في تقليل خطورة المضاعفات (على سبيل المثال: خراجات في البطن، التهاب البنكرياس) بعد الخضوع لجراحة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لإيقاف النزيف والحماية من <strong>تكراره الناتج من دوالي المعدة والمريء المتمزقة</strong> في المرضى الذين يُعانون من تليُّف الكبد (مرض كبدي مُزمِن). يُساعِد العلاج بدواء ساندوستاتين على التحكم في النزيف وتقليل الحاجة إلى نقل الدَّم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لعلاج أورام الغدة النخامية التي تنتج كمية أكثر مما يجب من الهرمون المنبه للغدة الدَّرقية. قد يُؤدي وجود كمية أكثر مما يجب من الهرمون المنبه للغدة الدَّرقية إلى التعرُّض إلى فرط نشاط الغدة الدَّرقية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُستَخدَم دواء ساندوستاتين لعلاج الأشخاص المُصابين بأورام الغدة النخامية التي تنتج كمية أكثر مما يجب من الهرمون المنبه للغدة الدَّرقية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عندما تكون أنواع العلاج الأخرى (الجراحة أو العلاج الإشعاعي) غير مناسبة أو لم تعمل.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعد العلاج الإشعاعي، ليشمل الفترة المؤقتة التي يستغرقها العلاج الإشعاعي حتى يصبح فعَّالًا تمامًا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أ&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>موانع استعمال </strong><strong>دواء</strong><strong> ساندوستاتين</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">-إذا كنت تعاني من حساسية من أوكتريوتايد أومن أي مكون من المكونات الأخرى بهذا الدَّواء (المدرجة في قسم: 6).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ب&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الاحتياطات عند استعمال </strong><strong>دواء</strong><strong> ساندوستاتين</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">تحدَّث إلى طبيبك قبل استخدام دواء ساندوستاتين:</p><p dir="RTL">&nbsp;</p><p dir="RTL">-إذا كنت تعلم أنك مُصاب بحصى في المرارة في الوقت الحالي، أو أُصِبت بها في الماضي أو تعاني من أي مضاعفات مثل الحمى أو القشعريرة أو آلام البطن أو اصفرار الجلد أو العينين ، فأخبِر طبيبك؛ إذ قد يُؤدي استخدام دواء ساندوستاتين إلى تكوين حصى في المرارة. قد يرغب طبيبك في إجراء فحص للمرارة بصفة دورية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-إذا كان لديك مشاكل بمستويات السكر في الدَّم، سواء كان مرتفعًا جدًّا (كما هو الحال في مرض السُّكَّرِي) أو منخفضًا جدًّا (نقص سكر الدَّم). عندما يُستَخدَم دواء ساندوستاتين لعلاج النزيف النَّاجم عن دوالي المعدة والمريء، تكون مراقبة مستوى السكر واجبة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-إذا كان لديك تاريخ مَرَضي &nbsp;من نقص &nbsp;فيتامين ب12 فقد يرغب طبيبك في فحص مستوى فيتامين ب12 لديك بصفة دورية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-قد يخفض أوكتريوتيد معدل ضربات القلب وقد يؤدي تناول جرعات عالية منه إلى اضطراب نظم القلب. قد يراقب طبيبك معدل ضربات قلبك أثناء العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاختبارات والفحوصات</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا تلقيت علاجًا بدواء ساندوستاتين على مدار فترة زمنية طويلة، فقد يرغب طبيبك في فحص وظائف الغدة الدَّرقية لديك بصفة دورية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيقوم طبيبك بفحص وظائف الكبد لديك.</p><p dir="RTL">قد يرغب طبيبك في فحص وظائف إنزيم البنكرياس.</p><p dir="RTL"><strong>الأطفال</strong></p><p dir="RTL">هناك معلومات محدودة بشأن استخدام دواء ساندوستاتين للأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ج. </strong><strong>التداخلات الدوائية من أخذ </strong><strong>دواء</strong><strong> ساندوستاتين مع أدوية أخرى</strong></p><p dir="RTL">يُرجى إبلاغ الطبيب أو الصيدلي الخاص بك إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أيَّة أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُمكِنك مواصلة تناول أدوية أخرى بشكل عام أثناء العلاج بدواء ساندوستاتين. مع ذلك، تم الإبلاغ عن تأثر بعض الأدوية بدواء ساندوستاتين، مثل سيميتيدين، سيكلوسبورين، بروموكريبتين، كينيدين وتيرفينادين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تتناول دواء للتَّحكم في ضغط الدَّم &nbsp;(على سبيل المثال: أحد حاصرات بيتا أو أحد حاصرات قناة الكالسيوم) أو دواء للتحكم في توازن السّوائل والكهارل، فقد يحتاج طبيبك إلى تعديل الجرعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت مُصابًا بمرض السُّكَّرِي، فقد يحتاج طبيبك إلى تعديل جرعة الأنسولين.</p><p dir="RTL">إذا كنت ستتلقى lutetium (177Lu) oxodotreotide ، وهو علاج صيدلاني إشعاعي ، فقد يتوقف طبيبك و / أو يكيف علاج ساندوستاتين.</p><p dir="RTL"><strong>د. الحمل والرضاعة </strong></p><p dir="RTL">إذا كنتِ حامل أو مرضعه أو تظنين أنكِ حامل أو تخططين لذلك، فاستشيري طبيبك قبل استخدام هذا الدَّواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب أن يُستَخدَم دواء ساندوستاتين فقط أثناء الحَمْل إذا كانت هناك حاجة مُلِحّة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب على السيدات ممن لديهن القدرة على الحَمْل استخدام وسيلة فعَّالة لمنع الحَمْل أثناء العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تمارسي الرضاعة الطبيعية أثناء استخدام دواء ساندوستاتين. من غير المعروف ما إذا كان يمر دواء ساندوستاتين إلى لبن الثدي أم لا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>هـ. تأثير </strong><strong>دواء</strong><strong> ساندوستاتين على القيادة واستخدام الآلات</strong></p><p dir="RTL">&nbsp;ليس لدواء ساندوستاتين تأثير أو هناك تأثير لا يكاد يذكر في القدرة على القيادة واستخدام الآلات. مع ذلك هناك بعض الأعراض الجانبية التي قد تعاني منها أثناء استخدام دواء ساندوستاتين، مثل: الصداع والتَّعب، قد تحد من قدرتك على القيادة واستخدام الآلات بأمان.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>و. </strong><strong>معلومات هامة حول بعض مكونات </strong><strong>دواء</strong><strong> ساندوستاتين</strong></p><p dir="RTL"><strong>يحتوي </strong><strong>دواء</strong><strong> ساندوستاتين</strong> <strong>على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من 1 ملليمول صوديوم (23 مجم) لكل أمبولة / قنينة، ذلك بالقول انه &quot;خالٍ من الصوديوم&quot; بشكل أساسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">استخدم دائمًا هذا الدَّواء بالضبط كما أخبرك طبيبك أو الصيدلي الخاص بك. راجع طبيبك أو الصيدلي الخاص بك إذا لم تكن متأكدًا من كيفية الاستخدام.</p><p dir="RTL">&nbsp;</p><p dir="RTL">وفقًا للحالة الخاضعة للعلاج، يُعطى دواء ساندوستاتين عن طريق:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحَقن أسفل الجلد أو</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التَّسريب الوريدي (في الوريد).</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت مُصابًا بتليُّف الكبد (مرض كبدي مُزمِن)، فقد يحتاج طبيبك إلى تعديل جرعة المداومة (المستمرة).</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيشرح لك طبيبك أو الممرض الخاص بك كيفية حَقْن دواء ساندوستاتين أسفل الجلد، ولكن يجب أيضًا أن يتم التَّسريب في الوريد دائمًا من قِبَل أخصائي الرّعاية الصحية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الحَقن</strong> <strong>أسفل الجلد</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يُعد الجزء العلوي من الذراع، الفخذين والبطن مناطق جيدة للحقن أسفل الجلد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">اختر موضعًا جديدًا لكل عملية حَقْن أسفل الجلد؛ بحيث لا يحدث تهيُّج في منطقة معينة. يجب على المرضى الذين سيحقنون أنفسهم تلقي تعليمات دقيقة من الطبيب أو الممرض.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا حفظت الدَّواء في الثلاجة، يُوصى بأن تسمح له بالوصول إلى درجة حرارة الغرفة قبل استخدامه. سيقلل هذا خطر الشعور بألم في موضع الحَقْن. يُمكِنك تدفئته في يدك ولكن لا تعرضه للتَّسخين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يتعرَّض عدد قليل من الأشخاص لألم في موضع الحَقْن أسفل الجلد. يستمر هذا الألم عادةً لفترة قصيرة فقط. إذا حدث هذا لك، فيُمكِنك تخفيف ذلك عن طريق تدليك موضع الحَقْن لبضعة ثوان بعد ذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قبل استخدام دواء ساندوستاتين أمبول، افحص المحلول تحسبًا لوجود جسيمات أو تغير في اللون. لا تستخدمه إذا رأيت أي شيء غير مُعتاد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أ&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الجرعة الزائدة من </strong><strong>دواء</strong><strong> ساندوستاتين</strong></p><p dir="RTL">أعراض الجرعة الزَّائدة هي: ضربات قلب غير منتظمة، انخفاض ضغط الدَّم، سكتة قلبية، انخفاض إمداد الأكسجين للمخ، ألم شديد في الجزء العلوي من المعدة، اصفرار الجلد والعينين، غثيان، فقدان الشهية، إسهال، ضعف، تعب، نقص الطاقة، فقدان الوزن، تورُّم البطن، شعور غير مريح وارتفاع مستوى حمض اللاكتيك في الدَّم&nbsp;&nbsp;وعدم انتظام ضربات القلب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تعتقد أنك قد تلقيت جرعة زائدة وواجهت هذه الأعراض، فأخبر طبيبك فورًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ب&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>نسيان تناول جرعة من </strong><strong>دواء</strong><strong> ساندوستاتين</strong></p><p dir="RTL">تناول جرعة واحدة بمجرد تذكرك، ثم واصل علاجك كالمُعتاد. لن يُلحِق بك الدواء أي ضرر إذا نسيت تناول جرعة، ولكن قد تتعرض لتكرار الظهور المؤقت لبعض الأعراض حتى الرجوع إلى الجدول المُحَدد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تقم بحقن جرعة مضاعفة من دواء ساندوستاتين لتعويض جرعة قد .</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ج. التوقف عن تناول </strong><strong>دواء</strong><strong> ساندوستاتين</strong></p><p dir="RTL">إذا أوقفت علاجك بدواء ساندوستاتين فقد تعود الأعراض في الظهور لديك مرة أخرى. لذلك، لا تتوقف عن تناول دواء ساندوستاتين ما لم يخبرك الطبيب بذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدَّواء، فاستشر الطبيب أو الممرض أو الصيدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الأدوية، قد يُسبب هذا الدَّواء آثارًا جانبية، على الرَّغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>بعض ا</strong><strong>لأعراض</strong><strong> الجانبية قد تكون خطيرة. أخبر طبيبك على الفور إذا تعرضت لأي مما يلي:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة جدًّا </strong>(قد تُؤثر على أكثر من 1 من بين كل 10&nbsp;أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حصى في المرارة، تُؤدي إلى ألم مفاجئ بالظهر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود كمية أكثر مما يجب من السكر في الدَّم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة</strong> (قد تُؤثر على ما يصل إلى شخص واحد من بين كل ١٠&nbsp;أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض نشاط الغدة الدَّرقية (قصور الغدة الدَّرقية) الذي يُسبب تغيُّرات في مُعدَّل ضربات القلب أو الشهية أو الوزن، تعب، شعور بالبرودة، أو تورُّم في الجزء الأمامي من الرقبة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيُّرات في اختبارات وظائف الغدة الدرقية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المرارة ، قد تشمل الأعراض: ألم في الجزء العلوي الأيمن من البطن، الحُمّى، الغثيان، اصفرار الجلد والعينين (يرقان).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود كمية قليلة جدًّا من السكر بالدَّم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلل في تحمل الجلوكوز.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بطء ضربات قلب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة</strong> (قد تُؤثر على ما يصل إلى شخص واحد من بين كل ١٠٠ شخص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عطش، انخفاض في كمية البول ، بول داكن، جلد أحمر جاف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تسارع ضربات القلب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية الخطيرة الأخرى</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات فرط الحساسية (الحساسية) وتشمل: الطفح الجلدي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أحد أنواع تفاعلات الحساسية (الحساسية المفرطة) التي قد تُسبب صعوبة في البلع أو التنفس، تورُّم ووخز، ربما مع هبوط في ضغط الدَّم مع دوخة أو فقدان الوعي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس ، قد تشمل الأعراض: ألم مفاجئ في الجزء العلوي من البطن، الغثيان، القيء، الإِسْهال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكبد ، قد تشمل الأعراض: اصفرار الجلد والعينين (يرقان)، الغثيان، القيء، فقدان الشهية، شعور عام بالتوعك، حكة، بول فاتح اللون.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم انتظام ضربات القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى تعداد الصَّفائح الدَّموية في الدَّم ، قد يُؤدي هذا إلى زيادة النزيف أو ظهور كدمات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك على الفور إذا لاحظت أي من الأعراض الجانبية المذكورة أعلاه.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأعراض الجانبية الأخرى:</strong></p><p dir="RTL">أخبِر طبيبك أو الصيدلي الخاص بك أو الممرض إذا لاحظت أي من الأعراض الجانبية المُدرَجة أدناه. تكون عادةً طفيفة وتميل إلى الاختفاء مع العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة جدًّا </strong>(قد تُؤثر على أكثر من 1 من بين كل 10&nbsp;أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إِسْهال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالبطن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إمساك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتفاخ البطن (ريح).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم موضعي بموضع الحقن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة</strong> (قد تُؤثر على ما يصل إلى شخص واحد من بين كل ١٠&nbsp;أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور غير مريح بعد تناول الوجبات (عُسْرُ الهَضْم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قيء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شهور بالامتلاء في المعدة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; براز دهني.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; براز ليِّن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيُّر لون البراز.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير في اختبارات وظائف الكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق التَّنفس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا ظهرت لديك أية أعراض جانبية، فتحدَّث إلى الطبيب أو الممرض أو الصيدلي الخاص بك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يتعرَّض عدد قليل من الأشخاص لألم في موضع الحَقْن أسفل الجلد. يستمر هذا الألم عادةً لفترة قصيرة فقط. إذا حدث هذا لك، فيُمكِنك تخفيف ذلك عن طريق تدليك موضع الحَقْن لبضعة ثوان بعد ذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تتناول دواء ساندوستاتين عن طريق الحَقْن أسفل الجلد، فقد يُساعِد على تقليل خطر الإصابة بأعراض جانبية بالجهاز الهضمي إذا تجنبت تناول الوجبات في وقت قريب من موعد الحَقْن. لذا من المُوصى به أن تحقن دواء ساندوستاتين بين الوجبات أو عند الذهاب إلى النوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">إذا أُصبت بأي أعراض جانبية، فتحدَّث إلى طبيبك أو الصيدلي أو الممرض.ويشمل ذلك أية آثار جانبية مُحتمَلة، غير المُدرجة في هذه النَّشرة.من خلال إبلاغك عن الآثار الجانبية، يمكنك المساعدة في توفير معلومات إضافية حول أمان استخدام هذا الدَّواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ هذا الدَّواء بعيدًا عن رؤية ومُتناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب التَّخزين داخل العبوة الأصلية للحماية من الضوء.</p><p dir="RTL">يحفظ في الثلاجة (عند 2 ‑ 8 درجة مئوية). لا تعرضه للتَّجميد.</p><p dir="RTL">يُمكِن أن يُحفَظ الأمبول (100 ميكروجرام/ ملليلتر) في درجة حرارة أقل من 30 درجة مئوية لمدة تصل إلى أسبوعين.</p><p dir="RTL">يجب استخدام الأمبولات فورًا بعد الفتح.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب استخدام المحاليل المخففة فور إعدادها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستعمل هذا الدَّواء بعد انتهاء تاريخ الصَّلاحية المدون على الملصق والكرتون بعد كلمة &quot;EXP&quot;.&nbsp; يُشير تاريخ انتهاء الصَّلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدَّواء إذا لاحظت وجود جسيمات أو تغير في لونه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من الأدوية عن طريق إلقائها في مياه الصَّرف أو مع المخلفات المنزلية. استشر الصيدلي الخاص بك عن كيفية التَّخلص من الأدوية التي لم تَعُد تستخدمها. ستُساعد هذه الإجراءات في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>المادة الفعالة هي أوكتريوتايد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دواء ساندوستاتين 0,1 مجم &nbsp;/ 1 ملل:&nbsp; يحتوي كل 1 ملليلتر من المحلول على 100 ميكروجرام أوكتريوتايد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي:</p><p dir="RTL">في الأمبولات: حمض اللاكتيك، مانيتول (E421)، كربونات الصوديوم الهيدروجينية، ماء للحَقْن.</p><p dir="RTL">في زجاجات متعددة الجرعات: حمض اللاكتيك، فينول، مانيتول (E421)، كربونات الصوديوم الهيدروجينية، ماء للحَقْن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أمبولات:</p><p dir="RTL">زجاجة عديمة اللون تحتوي على محلول صافي وعديم اللون.</p><p dir="RTL">عبوات بها ثلاثة وخمسة وستة وعشرة أمبولات وعشرون وخمسون أمبولًا.</p><p dir="RTL">عبوات متعددة بها عشر عبوات، تحتوي كل منها على ثلاثة أمبولات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">زجاجات متعددة الجرعات:</p><p dir="RTL">زجاجة عديمة اللون بغطاء من المطاط الخالي من مادة اللاتكس (مطاط أيزوبيوتيلين-أيزوبرين) تحتوي على محلول صافٍ وعديم اللون.</p><p dir="RTL">عبوات بها زجاجة واحدة وخمس زجاجات.</p><p dir="RTL">قد لا یتم تسویق جمیع العبوات في دولتك.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مالك حق التسويق لهذا المنتج هي شركة نوفارتس فارما إيه جي.</p><p>www.Novartis.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            د‌.تم اعتماد هذه النَّشرة من قبل المملكة المتحدة  في 07/2021 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sandostatin 100 microgram/1 ml, solution for injection/infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One ampoule of 1 ml contains100 microgram octreotide (as octreotide acetate)

Excipient(s) with known effect
Contains less than 1 mmol (23 mg) sodium per ampoule/vial, that is to say essentially “sodium-free”.

For the full list of excipients see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection/infusion.
Clear, colourless solution.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptomatic control and reduction of growth hormone (GH) and IGF‑1 plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. Sandostatin is also indicated for acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective.</p><p>&nbsp;</p><p>Relief of symptoms associated with functional gastro‑entero‑pancreatic (GEP) endocrine tumours, e.g. carcinoid tumours with features of the carcinoid syndrome (see section&nbsp;5.1).</p><p>&nbsp;</p><p>Sandostatin is not an anti‑tumour therapy and is not curative in these patients.</p><p>&nbsp;</p><p>Prevention of complications following pancreatic surgery.</p><p>&nbsp;</p><p>Emergency management to stop bleeding and to protect from re‑bleeding owing to gastro‑oesophageal varices in patients with cirrhosis. Sandostatin is to be used in association with specific treatment such as endoscopic sclerotherapy.</p><p>&nbsp;</p><p>Treatment of TSH‑secreting pituitary adenomas:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; when secretion has not normalised after surgery and/or radiotherapy;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in patients in whom surgery is inappropriate;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in irradiated patients, until radiotherapy is effective.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>&nbsp;</p><p><em>Acromegaly</em></p><p>Initially 0.05 to 0.1&nbsp;mg by subcutaneous (s.c.) injection every 8 or 12&nbsp;hours. Dosage adjustment should be based on monthly assessment of GH and IGF‑1 levels (target: GH &lt;2.5&nbsp;ng/mL; IGF‑1 within normal range) and clinical symptoms, and on tolerability. In most patients, the optimal daily dose will be 0.3&nbsp;mg. A maximum dose of 1.5&nbsp;mg per day should not be exceeded. For patients on a stable dose of Sandostatin, assessment of GH and IGF-1 should be made every 6&nbsp;months.</p><p>&nbsp;</p><p>If no relevant reduction in GH levels and no improvement in clinical symptoms have been achieved within 3&nbsp;months of starting treatment with Sandostatin, therapy should be discontinued.</p><p>&nbsp;</p><p><em>Gastro‑entero‑pancreatic endocrine tumours</em></p><p>Initially 0.05&nbsp;mg once or twice daily by s.c. injection. Depending on clinical response, effect on levels of tumour‑produced hormones (in cases of carcinoid tumours, on the urinary excretion of 5‑hydroxyindole acetic acid), and on tolerability, dosage can be gradually increased to 0.1 to 0.2&nbsp;mg 3&nbsp;times daily. Under exceptional circumstances, higher doses may be required. Maintenance doses have to be adjusted individually.</p><p>&nbsp;</p><p>In carcinoid tumours, if there is no beneficial response within 1&nbsp;week of treatment with Sandostatin at the maximum tolerated dose, therapy should not be continued.</p><p>&nbsp;</p><p><em>Complications following pancreatic surgery</em></p><p>0.1&nbsp;mg 3&nbsp;times daily by s.c. injection for 7&nbsp;consecutive days, starting on the day of surgery at least 1&nbsp;hour before laparotomy.</p><p>&nbsp;</p><p><em>Bleeding gastro‑oesophageal varices</em></p><p>25&nbsp;micrograms/hour for 5&nbsp;days by continuous intravenous (i.v.) infusion. Sandostatin can be used in dilution with physiological saline.</p><p>&nbsp;</p><p>In cirrhotic patients with bleeding gastro‑oesophageal varices, Sandostatin has been well tolerated at continuous i.v. doses of up to 50&nbsp;micrograms/hour for 5&nbsp;days.</p><p>&nbsp;</p><p><em>Treatment of TSH‑secreting pituitary adenomas</em></p><p>The dosage most generally effective is 100&nbsp;micrograms three times a day by s.c. injection. The dose can be adjusted according to the responses of TSH and thyroid hormones. At least 5&nbsp;days of treatment will be needed to judge the efficacy.</p><p>&nbsp;</p><p><em>Use in the elderly</em></p><p>There is no evidence of reduced tolerability or altered dosage requirements in elderly patients treated with Sandostatin.</p><p>&nbsp;</p><p><em>Use in children</em></p><p>Experience with Sandostatin in children is limited.</p><p>&nbsp;</p><p><em>Use in patients with impaired liver function</em></p><p>In patients with liver cirrhosis, the half‑life of the drug may be increased, necessitating adjustment of the maintenance dosage.</p><p>&nbsp;</p><p><em>Use in patients with impaired renal function</em></p><p>Impaired renal function did not affect the total exposure (AUC) to octreotide administered as s.c. injection, therefore no dose adjustment of Sandostatin is necessary.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p><u>&nbsp;</u></p><p>Sandostatin may be administered directly by subcutaneous (s.c.) injection or by intravenous (i.v.) infusion after dilution. For further instructions on handling and instructions for dilution of the medicinal product, refer to section 6.6.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Known hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>General</u></p><p>&nbsp;</p><p>As GH-secreting pituitary tumours may sometimes expand, causing serious complications (e.g. visual field defects), it is essential that all patients be carefully monitored. If evidence of tumour expansion appears, alternative procedures may be advisable.</p><p>&nbsp;</p><p>The therapeutic benefits of a reduction in growth hormone (GH) levels and normalisation of insulin-like growth factor 1 (IGF-1) concentration in female acromegalic patients could potentially restore fertility.&nbsp; Female patients of childbearing potential should be advised to use adequate contraception if necessary during treatment with octreotide (see section 4.6).</p><p>&nbsp;</p><p>Thyroid function should be monitored in patients receiving prolonged treatment with octreotide.</p><p>&nbsp;</p><p>Hepatic function should be monitored during octreotide therapy.</p><p>&nbsp;</p><p><u>Cardiovascular related events</u></p><p>&nbsp;</p><p>Common cases of bradycardia have been reported.&nbsp; Dose adjustments of medicinal products such as beta blockers, calcium channel blockers, or agents to control fluid and electrolyte balance, may be necessary (see section 4.5).</p><p>Atrioventricular blocks (including complete atrioventricular block) were reported in patients receiving high doses of continuous infusion (100 micrograms/hour) and in patients receiving bolus octreotide intravenously (50 micrograms bolus followed by 50 micrograms/hour continuous infusion). The maximum dose of 50 microgram/hour should therefore not be exceeded (see section 4.2). Patients who receive high doses of intravenous octreotide should be kept under appropriate cardiac monitoring.</p><p><u>Gallbladder and related events</u></p><p>&nbsp;</p><p>Cholelithiasis is a very common event during Sandostatin treatment and may be associated with cholecystitis and biliary duct dilatation (see section 4.8). Additionally, cases of cholangitis have been reported as a complication of cholelithiasis in patients taking Sandostatin in the post-marketing setting.<em> </em>Ultrasonic examination of the gallbladder before, and at about 6‑ to 12‑month intervals during Sandostatin therapy is therefore recommended.</p><p>&nbsp;</p><p><u>GEP endocrine tumours</u></p><p>&nbsp;</p><p>During the treatment of GEP endocrine tumours, there may be rare instances of sudden escape from symptomatic control by Sandostatin, with rapid recurrence of severe symptoms. If the treatment is stopped, symptoms may worsen or recur.</p><p>&nbsp;</p><p><u>Glucose metabolism</u></p><p>&nbsp;</p><p>Because of its inhibitory action on growth hormone, glucagon, and insulin, Sandostatin may affect glucose regulation. Post-prandial glucose tolerance may be impaired and, in some instances, the state of persistent hyperglycaemia may be induced as a result of chronic administration. Hypoglycaemia has also been reported.</p><p>&nbsp;</p><p>In patients with insulinomas, octreotide, because of its greater relative potency in inhibiting the secretion of GH and glucagon than that of insulin, and because of the shorter duration of its inhibitory action on insulin, may increase the depth and prolong the duration of hypoglycaemia. These patients should be closely monitored during initiation of Sandostatin therapy and at each change of dosage. Marked fluctuations in blood glucose concentration may possibly be reduced by smaller, more frequently administered doses.</p><p>&nbsp;</p><p>Insulin requirements of patients with type I diabetes mellitus therapy may be reduced by administration of Sandostatin. In non‑diabetics and type II diabetics with partially intact insulin reserves, Sandostatin administration can result in post-prandial increases in glycaemia. It is therefore recommended to monitor glucose tolerance and antidiabetic treatment.</p><p>&nbsp;</p><p><u>Oesophageal varices</u></p><p>&nbsp;</p><p>Since, following bleeding episodes from oesophageal varices, there is an increased risk for the development of insulin‑dependent diabetes or for changes in insulin requirement in patients with pre‑existing diabetes, an appropriate monitoring of blood glucose levels is mandatory.</p><p>&nbsp;</p><p><u>Local Site Reactions</u></p><p>&nbsp;</p><p>In a 52-week toxicity study in rats, predominantly in males, sarcomas were noted at the s.c. injection site only at the highest dose (about 8 times the maximum human dose based on body surface area). No hyperplastic or neoplastic lesions occurred at the s.c. injection site in a 52-week dog toxicity study. There have been no reports of tumour formation at the injection sites in patients treated with Sandostatin for up to 15 years. All the information available at present indicates that the findings in rats are species specific and have no significance for the use of the drug in humans (see section 5.3).</p><p>&nbsp;</p><p><u>Nutrition</u></p><p>&nbsp;</p><p>Octreotide may alter absorption of dietary fats in some patients.</p><p>&nbsp;</p><p>Depressed vitamin B12 levels and abnormal Schilling&rsquo;s tests have been observed in some patients receiving octreotide therapy.&nbsp; Monitoring of vitamin B12 levels is recommended during therapy with Sandostatin in patients who have a history of vitamin B12 deprivation.</p><p><u>Pancreatic function</u></p><p>&nbsp;</p><p>Pancreatic exocrine insufficiency (PEI) has been observed in some patients receiving octreotide therapy for gastroenteropancreatic neuroendocrine tumours. Symptoms of PEI can include steatorrhea, loose stools, abdominal bloating and weight loss. Screening and appropriate treatment for PEI according to clinical guidelines should be considered in symptomatic patients.</p><p><u>Sodium content</u></p><p>&nbsp;</p><p>Sandostatin contains less than 1 mmol (23 mg) sodium per ampoule/vial, that is to say essentially &ldquo;sodium-free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dose adjustment of medicinal products such as beta blockers, calcium channel blockers, or agents to control fluid and electrolyte balance may be necessary when Sandostatin is administered concomitantly (see section&nbsp;4.4).</p><p>&nbsp;</p><p>Dose adjustments of insulin and antidiabetic medicinal products may be required when Sandostatin is administered concomitantly (see section&nbsp;4.4).</p><p><strong>&nbsp;</strong></p><p>Sandostatin has been found to reduce the intestinal absorption of ciclosporin and to delay that of cimetidine.</p><p><strong>&nbsp;</strong></p><p>Concomitant administration of octreotide and bromocriptine increases the bioavailability of bromocriptine.</p><p>&nbsp;</p><p>Limited published data indicate that somatostatin analogues might decrease the metabolic clearance of compounds known to be metabolised by cytochrome P450 enzymes, which may be due to the suppression of growth hormone. Since it cannot be excluded that octreotide may have this effect, other drugs mainly metabolised by CYP3A4 and which have a low therapeutic index should therefore be used with caution (e.g. &nbsp;quinidine, terfenadine).</p><p>Concomitant use with radioactive somatostatin analogues</p><p>&nbsp;</p><p>Somatostatin and its analogues such as octreotide competitively bind to somatostatin receptors and may interfere with the efficacy of radioactive somatostatin analogues.</p><p>The administration of Sandostatin should be avoided for 24 hours prior to the administration of lutetium (177Lu) oxodotreotide, a radiopharmaceutical binding to somatostatin receptors.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p><u>&nbsp;</u></p><p>There is a limited amount of data (less than 300&nbsp;pregnancy outcomes) from the use of octreotide in pregnant women, and in approximately one third of the cases the pregnancy outcomes are unknown. The majority of reports were received after post‑marketing use of octreotide and more than 50% of exposed pregnancies were reported in patients with acromegaly. Most women were exposed to octreotide during the first trimester of pregnancy at doses ranging from 100‑1200&nbsp;micrograms/day of Sandostatin s.c. or 10‑40&nbsp;mg/month of Sandostatin LAR. Congenital anomalies were reported in about 4% of pregnancy cases for which the outcome is known. No causal relationship to octreotide is suspected for these cases.</p><p>&nbsp;</p><p>Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section&nbsp;5.3).</p><p>&nbsp;</p><p>As a precautionary measure, it is preferable to avoid the use of Sandostatin during pregnancy (see section&nbsp;4.4).</p><p>&nbsp;</p><p><u>Breastfeeding</u></p><p><u>&nbsp;</u></p><p>It is unknown whether octreotide is excreted in human breast milk.&nbsp; Animal studies have shown excretion of octreotide in breast milk.&nbsp; Patients should not breast-feed during Sandostatin treatment.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>It is not known whether octreotide has an effect on human fertility. Late descent of the testes was found for male offsprings of dam treated during pregnancy and lactation. Octreotide, however, did not impair fertility in male and female rats at doses of up to 1&nbsp;mg/kg body weight per day (see section&nbsp;5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sandostatin has no or negligible influence on the ability to drive and use machines. Patients should be advised to be cautious when driving or using machines if they experience dizziness, asthenia/fatigue, or headache during treatment with Sandostatin.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>a.Summary of the safety profile</u></p><p>&nbsp;</p><p>The most frequent adverse reactions reported during octreotide therapy include gastrointestinal&nbsp; disorders, nervous system disorders, hepatobiliary disorders, and metabolism and nutritional disorders.</p><p>&nbsp;</p><p>The most commonly reported adverse reactions in clinical trials with octreotide administration were diarrhoea, abdominal pain, nausea, flatulence, headache, cholelithiasis, hyperglycaemia and constipation. Other commonly reported adverse reactions were dizziness, localised pain, biliary sludge, thyroid dysfunction (e.g. decreased thyroid stimulating hormone [TSH], decreased total T4, and decreased free T4), loose stools, impaired glucose tolerance, vomiting, asthenia, and hypoglycaemia.</p><p>&nbsp;</p><p><u>b.Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>The following adverse drug reactions, listed in Table 1, have been accumulated from clinical studies with octreotide:</p><p>&nbsp;</p><p>Adverse drug reactions (Table 1) are ranked under heading of frequency, the most frequent first, using the following convention: very common (&sup3; 1/10); common (&sup3; 1/100, &lt; 1/10); uncommon (&sup3; 1/1,000, &le; 1/100); rare (&sup3; 1/10,000, &le; 1/1,000) very rare (&le; 1/10,000), including isolated reports.&nbsp;&nbsp; Within each frequency grouping, adverse reactions are ranked in order of decreasing seriousness.</p><p>&nbsp;</p><p><strong>Table 1&nbsp; Adverse drug reactions reported in clinical studies</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:95%"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Diarrhoea, abdominal pain, nausea, constipation, flatulence.</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Dyspepsia, vomiting, abdominal bloating, steatorrhoea, loose stools, discolouration of faeces.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Headache.</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Dizziness.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Endocrine disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Hypothyroidism, thyroid disorder (e.g. decreased TSH, decreased total T4, and decreased free T4).</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Cholelithiasis.</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Cholecystitis, biliary sludge, hyperbilirubinaemia.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Hyperglycaemia.</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Hypoglycaemia, impaired glucose tolerance, anorexia.</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Dehydration.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Injection site reactions.</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Asthenia.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Investigations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Elevated transaminase levels.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Pruritus, rash, alopecia.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Respiratory disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Dyspnoea.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Bradycardia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Tachycardia.</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Post-marketing</u></p><p>Spontaneously reported adverse reactions presented in Table 2, are reported voluntarily and it is not always possible to reliably establish frequency or a causal relationship to drug exposure.&nbsp;</p><p>&nbsp;</p><p>Table 2&nbsp; Adverse drug reactions derived from spontaneous reports</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:595px"><tbody><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune System disorders</strong></p><p>Anaphylaxis, allergy/hypersensitivity reactions.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Urticaria</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Acute pancreatitis, acute hepatitis without cholestasis, cholestatic hepatitis, cholestasis, jaundice, cholestatic jaundice.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Arrhythmias.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Increased alkaline phosphatase levels, increased gamma glutamyl transferase levels.</p></td></tr></tbody></table><p>&nbsp;</p><p><u>c.Description of selected adverse reactions</u></p><p>&nbsp;</p><p><em>Gallbladder and related reactions</em></p><p>Somatostatin analogues have been shown to inhibit gallbladder contractility and decrease bile secretion, which may lead to gallbladder abnormalities or sludge. Development of gallstones has been reported in 15 to 30% of long-term recipients of s.c. Sandostatin. The incidence in the general population (aged 40 to 60 years) is 5 to 20%. If gallstones do occur, they usually asymptomatic; symptomatic stones should be treated either by dissolution therapy with bile acids or by surgery.</p><p><em>&nbsp;</em></p><p><em>Gastrointestinal disorders</em></p><p>In rare instances, gastrointestinal side effects may resemble acute intestinal obstruction, with progressive abdominal distension, severe epigastric pain, abdominal tenderness and guarding.</p><p>&nbsp;</p><p>The frequency of gastrointestinal adverse events is known to decrease over time with continued treatment.</p><p>&nbsp;</p><p>Occurrence of gastrointestinal side-effects may be reduced by avoiding meals around the time of Sandostatin s.c. administration, that is, by injecting between meals or on retiring to bed.</p><p>&nbsp;</p><p><em>Hypersensitivity and anaphylactic reactions</em></p><p>Hypersensitivity and allergic reactions have been reported during post-marketing experience. When these occur, they mostly affect the skin, rarely the mouth and airways. Isolated cases of anaphylactic shock have been reported.</p><p><em>&nbsp;</em></p><p><em>Injection site reactions</em></p><p>Pain or a sensation of stinging, tingling or burning at the site of s.c. injection, with redness and swelling, rarely lasting more than 15 minutes. Local discomfort may be reduced by allowing the solution to reach room temperature before injection, or by injecting a smaller volume using a more concentrated solution.</p><p>&nbsp;</p><p><em>Metabolism and nutrition disorders</em></p><p>Although measured faecal fat excretion may increase, there is no evidence to date that long- term treatment with octreotide has led to nutritional deficiency due to malabsorption.&nbsp;</p><p>&nbsp;</p><p><em>Pancreatic enzymes</em></p><p>In very rare instances, acute pancreatitis has been reported within the first hours or days of Sandostatin s.c. treatment and resolved on withdrawal of the drug.&nbsp; In addition, cholelithiasis induced pancreatitis has been reported for patients on long-term Sandostatin s.c. treatment.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Cardiac disorders</em></p><p>Bradycardia is a common adverse reaction with somatostatin analogues. In both acromegalic and carcinoid syndrome patients, ECG changes were observed such as QT prolongation, axis shifts, early repolarisation, low voltage, R/S transition, early R wave progression, and non-specific ST-T wave changes.&nbsp; The relationship of these events to octreotide acetate is not established because many of these patients have underlying cardiac diseases (see section 4.4).</p><p>&nbsp;</p><p><em>Thrombocytopenia</em></p><p>Thrombocytopenia has been reported during post-marketing experience, particularly during treatment with Sandostatin (i.v.) in patients with cirrhosis of the liver. This is reversible after discontinuation of treatment.</p><p><u>&nbsp;</u></p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions.</p><p>&nbsp;</p><p>To report any side effect(s):</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Arabia</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p>&nbsp;</p><p>o SFDA call center: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patient Safety Department Novartis Consulting AG - Saudi Arabia:</p><p>&nbsp;</p><p>o Toll Free Number: 8001240078</p><p>o Phone: +966112658100</p><p>o Fax: +966112658107</p><p>o Email: adverse.events@novartis.com</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp; Other GCC States:</p><p>-&nbsp; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A limited number of accidental overdoses of Sandostatin in adults and children have been reported.&nbsp; In adults, the doses ranged from 2,400-6,000 micrograms/day administered by continuous infusion (100-250 micrograms/hour) or subcutaneously (1,500 micrograms three times a day).&nbsp; The adverse events reported were arrhythmia, hypotension, cardiac arrest, brain hypoxia, pancreatitis, hepatic steatosis, diarrhoea, weakness, lethargy, weight loss, hepatomegaly, and lactic acidosis.</p><p>&nbsp;</p><p>In children, the doses ranged from 50-3,000 micrograms/day administered by continuous infusion (2.1-500 micrograms/hour) or subcutaneously (50-100 micrograms).&nbsp; The only adverse event reported was mild hyperglycaemia.</p><p>&nbsp;</p><p>No unexpected adverse events have been reported in cancer patients receiving Sandostatin at doses of 3,000-30,000 micrograms/day in divided doses subcutaneously.</p><p>&nbsp;</p><p>The management of overdosage is symptomatic.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Somatostatin and analogues, ATC code: H01CB02</p><p>&nbsp;</p><p>Octreotide is a synthetic octapeptide derivative of naturally occurring somatostatin with similar pharmacological effects, but with a considerably prolonged duration of action.&nbsp; It inhibits pathologically increased secretion of growth hormone (GH) and of peptides and serotonin produced within<strong> </strong>the GEP endocrine system.</p><p>&nbsp;</p><p>In animals, octreotide is a more potent inhibitor of GH, glucagon and insulin release than somatostatin is, with greater selectivity for GH and glucagon suppression.</p><p>&nbsp;</p><p>In healthy subjects Sandostatin has been shown to inhibit</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; release of GH stimulated by arginine, exercise- and insulin-induced hypoglycaemia,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; postprandial release of insulin, glucagon, gastrin, other peptides of the GEP endocrine system, and arginine-stimulated release of insulin and glucagon,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thyrotropin-releasing hormone (TRH)-stimulated release of thyroid-stimulating hormone (TSH).</p><p>&nbsp;</p><p>Unlike somatostatin, octreotide inhibits GH secretion preferentially over insulin and its administration is not followed by rebound hypersecretion of hormones (i.e. GH in patients with acromegaly).</p><p>&nbsp;</p><p>In acromegalic patients Sandostatin lowers plasma levels of GH and IGF‑1. A GH reduction by 50% or more occurs in up to 90% patients, and a reduction of serum GH to &lt;5&nbsp;ng/mL can be achieved in about half of the cases. In most patients Sandostatin markedly reduces the clinical symptoms of the disease, such as headache, skin and soft tissue swelling, hyperhidrosis, arthralgia, paraesthesia. In patients with a large pituitary adenoma, Sandostatin treatment may result in some shrinkage of the tumour mass.</p><p>&nbsp;</p><p>In patients with functional tumours of the GEP endocrine system, Sandostatin, because of its diverse endocrine effects, modifies a number of clinical features. Clinical improvement and symptomatic benefit occur in patients who still have symptoms related to their tumours despite previous therapies, which may include surgery, hepatic artery embolization, and various chemotherapies, e.g. streptozocin and 5‑fluorouracil.</p><p>&nbsp;</p><p><u>Sandostatin&#39;s effects in the different tumour types are as follows</u></p><p>&nbsp;</p><p><u>Carcinoid tumours</u>&nbsp;</p><p>&nbsp;</p><p>Administration of Sandostatin may result in improvement of symptoms, particularly of flushing and diarrhoea.&nbsp; In many cases, this is accompanied by a fall in plasma serotonin and reduced urinary excretion of 5-hydroxyindole acetic acid.</p><p>&nbsp;</p><p><u>VIPomas</u>&nbsp;</p><p>&nbsp;</p><p>The biochemical characteristic of these tumours is overproduction of vasoactive intestinal peptide (VIP).&nbsp; In most cases, administration of Sandostatin results in alleviation of the severe secretory diarrhoea typical of the condition, with consequent improvement in quality of life.&nbsp; This is accompanied by an improvement in associated electrolyte abnormalities, e.g.&nbsp; hypokalaemia, enabling enteral and parenteral fluid and electrolyte supplementation to be withdrawn. In some patients, computed tomography scanning suggests a slowing or arrest of progression of the tumour, or even tumour shrinkage, particularly of hepatic metastases.&nbsp; Clinical improvement is usually accompanied by a reduction in plasma VIP levels, which may fall into the normal reference range.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Glucagonomas</u>&nbsp;</p><p>&nbsp;</p><p>Administration of Sandostatin results in most cases in substantial improvement of the necrolytic migratory rash which is characteristic of the condition.&nbsp; The effect of Sandostatin on the state of mild diabetes mellitus which frequently occurs is not marked and, in general, does not result in a reduction of requirements for insulin or oral hypoglycaemic agents.&nbsp; Sandostatin produces improvement of diarrhoea, and hence weight gain, in those patients affected.&nbsp; Although administration of Sandostatin often leads to an immediate reduction in plasma glucagon levels, this decrease is generally not maintained over a prolonged period of administration, despite continued symptomatic improvement.</p><p>&nbsp;</p><p><u>Gastrinomas/Zollinger‑Ellison syndrome</u></p><p>&nbsp;</p><p>Therapy with proton pump inhibitors or H2 receptor blocking agents generally controls gastric acid hypersecretion. However, diarrhoea, which is also a prominent symptom, may not be adequately alleviated by proton pump inhibitors or H2 receptor blocking agents. Sandostatin can help to further reduce gastric acid hypersecretion and improve symptoms, including diarrhoea, as it provides suppression of elevated gastrin levels, in some patients.</p><p>&nbsp;</p><p><u>Insulinomas</u></p><p>&nbsp;</p><p>Administration of Sandostatin produces a fall in circulating immunoreactive insulin, which may, however, be of short duration (about 2 hours). In patients with operable tumours Sandostatin may help to restore and maintain normoglycaemia pre‑operatively. In patients with inoperable benign or malignant tumours, glycaemic control may be improved without concomitant sustained reduction in circulating insulin levels.</p><p>&nbsp;</p><p><u>Complications following pancreatic surgery</u></p><p>&nbsp;</p><p>For patients undergoing pancreatic surgery, the peri‑ and post‑operative administration of Sandostatin reduces the incidence of typical postoperative complications (e.g. pancreatic fistula, abscess and subsequent sepsis, postoperative acute pancreatitis).</p><p>&nbsp;</p><p><u>Bleeding gastro‑oesophageal varices</u></p><p>&nbsp;</p><p>In patients presenting with bleeding gastro‑oesophageal varices due to underlying cirrhosis, Sandostatin administration in combination with specific treatment (e.g. sclerotherapy) is associated with better control of bleeding and early re‑bleeding, reduced transfusion requirements, and improved 5‑day survival. While the precise mode of action of Sandostatin is not fully elucidated, it is postulated that Sandostatin reduces splanchnic blood flow through inhibition of vaso‑active hormones (e.g. VIP, glucagon).</p><p>&nbsp;</p><p><u>Treatment of TSH‑secreting pituitary adenomas</u></p><p>&nbsp;</p><p>The treatment effects of Sandostatin were prospectively observed in 21&nbsp;patients and pooled with series of 37&nbsp;published cases. Among 42&nbsp;patients with evaluable biochemical data, there were 81% of patients (n=34) with satisfactory results (at least 50% reduction of TSH and substantial reduction of thyroid hormones), whereas 67% (n=28) had normalisations of TSH and thyroid hormones. In these patients, the response was maintained throughout the duration of treatment (up to 61&nbsp;months, mean, 15.7&nbsp;months).</p><p>&nbsp;</p><p>Regarding clinical symptoms, a clear improvement was reported in 19 out of 32&nbsp;patients with clinical hyperthyroidism. Tumour volume reduction greater than 20% was observed in 11&nbsp;cases (41%) with a decrease greater than 50% in 4&nbsp;cases (15%). The earliest reduction was reported after 14&nbsp;days of treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p><strong>&nbsp;</strong></p><p>After s.c. injection, Sandostatin is rapidly and completely absorbed.&nbsp; Peak plasma concentrations are reached within 30 minutes.&nbsp;&nbsp;</p><p>&nbsp;</p><p><u>Distribution</u></p><p><strong>&nbsp;</strong></p><p>The volume of distribution is 0.27 L/kg and the total body clearance 160 mL/min. &nbsp;Plasma protein binding amounts to 65%.&nbsp; The amount of Sandostatin bound to blood cells is negligible.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>The elimination half-life after s.c. administration is 100 minutes.&nbsp; After i.v. injection, the elimination is biphasic, with half-lives of 10 and 90 minutes. Most of the peptide is eliminated via the faeces, while approximately 32% is excreted unchanged into the urine.</p><p>&nbsp;</p><p><u>Special patient population</u></p><p>&nbsp;</p><p>Impaired renal function did not affect the total exposure (AUC) to octreotide administered as s.c. injection.</p><p>&nbsp;</p><p>The elimination capacity may be reduced in patients with liver cirrhosis, but not in patients with fatty liver disease.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Acute and repeated dose toxicology, genotoxicity, carcinogenicity and reproductive toxicology studies in animals revealed no specific safety concerns for humans.</p><p>&nbsp;</p><p>Reproduction studies in animals revealed no evidence of teratogenic, embryo/foetal or other reproduction effects due to octreotide at parental doses of up to 1&nbsp;mg/kg/day. Some retardation of physiological growth was noted in the offspring of rats which was transient and attributable to GH inhibition brought about by excessive pharmacodynamic activity (see section&nbsp;4.6).</p><p>&nbsp;</p><p>No specific studies were conducted in juvenile rats. In the pre- and post-natal developmental studies, reduced growth and maturation was observed in the F1 offspring of dams given octreotide during the entire pregnancy and lactation period. Delayed descent of the testes was observed for male F1 offsprings, but fertility of the affected F1 male pups remained normal. Thus, the abovementioned observations were transient and considered to be the consequence of GH inhibition.</p><p><u>&nbsp;</u></p><p><u>Carcinogenicity/chronic toxicity</u></p><p>&nbsp;</p><p>In rats receiving octreotide acetate at daily doses up to 1.25&nbsp;mg/kg body weight, fibrosarcomas were observed, predominantly in a number of male animals, at the s.c. injection site after 52, 104 and 113/116&nbsp;weeks. Local tumours also occurred in the control rats, however development of these tumours was attributed to disordered fibroplasia produced by sustained irritant effects at the injection sites, enhanced by the acidic lactic acid/mannitol vehicle. This non-specific tissue reaction appeared to be particular to rats. Neoplastic lesions were not observed either in mice receiving daily s.c. injections of octreotide at doses up to 2&nbsp;mg/kg for 98&nbsp;weeks, or in dogs treated with daily s.c. doses of the drug for 52&nbsp;weeks.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactic acid</p><p>Mannitol (E421)</p><p>Sodium hydrogen carbonate</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6. Octreotide acetate is not stable in Total Parenteral Nutrition (TPN) solutions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
The product should be used immediately after opening.
Diluted solutions should be used immediately after preparation.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in the original package in order to protect from light.</p><p>Store in a refrigerator (2&deg;C to 8&deg;C). Do not freeze.</p><p>The ampoules may be stored below 30&deg;C for up to two weeks.</p><p>For storage conditions after opening and after dilution, refer to section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>One-point-cut colourless, type I&nbsp;glass ampoule with two colour code rings containing clear colourless solution.</p><p>Sandostatin 50 microgram/1 ml: one blue and one yellow.</p><p>Sandostatin 100 microgram/1 ml: one blue and one green.</p><p>Sandostatin 500 microgram/1 ml: one blue and one pink.</p><p>&nbsp;</p><p>Packs of three, five, six, ten, twenty and fifty ampoules packed in a cardboard tray which is placed in an outer box.</p><p>Multipacks of ten packs, each containing three ampoules</p><p>&nbsp;</p><p>Not all strengths or pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p><p><strong>Instructions for use and handling </strong></p><p>Ampoule (100 microgram/1&nbsp;ml) is intended for single use only; it should be opened just prior to administration and any unused portion discarded.</p><p><strong>&nbsp;</strong></p><p><strong>Subcutaneous administration </strong></p><p>Patients who are to self-administer the drug by s.c. injection must receive precise directions from the physician or the nurse.</p><p>&nbsp;</p><p>To reduce local discomfort, it is recommended that the solution should be at room temperature before injection. Multiple injections at short intervals at the same site should be avoided.</p><p>&nbsp;</p><p><strong>Intravenous infusion </strong></p><p>Parenteral drug products should be inspected visually for discoloration and particulate matter prior to administration. For intravenous infusion the product must be diluted prior to administration. Sandostatin (octreotide acetate) is physically and chemically stable for 24&nbsp;hours in sterile physiological saline solutions or sterile solutions of dextrose (glucose) 5%&nbsp;in water. However, because Sandostatin can affect glucose homeostasis, it is recommended that physiological saline solutions be used rather than dextrose. The diluted solutions are physically and chemically stable for at least 24&nbsp;hours below 25&deg;C. From a microbiological point of view, the diluted solution should be used immediately. If&nbsp; not used immediately, in-use storage times and conditions prior to use are the responsibility of the user.</p><p>&nbsp;</p><p>The contents of one 500 microgram ampoule should normally be dissolved in 60&nbsp;ml physiological saline, and the resulting solution should be infused by means of an infusion pump. This should be repeated as often as necessary until the prescribed duration of treatment is reached.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The Marketing Authorization Holder for this Product is Novartis Pharma AG.
www.novartis.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Approved by MHRA in July 2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>